Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients
Clinical trial NCT05844046 · RECRUITING
Trial details
- NCT number
- NCT05844046
- Sponsor
- Enrico De Toni
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-06
- Primary completion
- 2026-12-31
- Enrollment
- 83
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.